Germany

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: Fosun Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 16, 2020

Details:

BioNTech and Shanghai Fosun Pharmaceutical today announced an agreement to supply Mainland China with 100 million doses initially of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval.

MYR Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Gilead Sciences to Acquire MYR GmbH

Lead Product(s): Bulevirtide Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $1,762.0 million Upfront Cash: $1,400.0 million

Deal Type: Acquisition December 10, 2020

Details:

The acquisition will provide Gilead with Hepcludex™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.